Pfizer Experimental Lung Cancer Drug Sigvotatug Vedotin Misses Survival Goal
2026-06-22 20:42:43
Pfizer Inc. said its experimental drug sigvotatug vedotin failed to improve survival in patients with an advanced form of lung cancer that couldn’t be treated with surgery, according to Bloomberg.
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Previous article：
AI趋势 | IBM盘后涨2%，宣布与OpenAI合作
